GWAS of erectile dysfunction (ED) in 6,175 cases among 223,805 European men identified one new 54 locus at 6q16.3 (lead variant rs57989773, OR 1.20 per C-allele; p = 5.71×10 -14 ), located between 55 MCHR2 and SIM1. In-silico analysis suggests SIM1 to confer ED risk through hypothalamic 56 dysregulation; Mendelian randomization indicates genetic risk of type 2 diabetes causes ED. Our 57 findings provide novel insights into the biological underpinnings of ED. 58 syncope, orthostatic hypotension and urinary incontinence ( Figure S3 ). The effects on blood pressure 131 and adiposity seen in patients with rare coding variants in SIM1 are recapitulated in individuals 132 harbouring the common ED-risk variant at the 6q16.3 locus ( Figure 1D, Supplementary Figure S3 ),
Erectile dysfunction (ED) is the inability to develop or maintain a penile erection adequate for sexual 60 intercourse 1 . ED has an age-dependent prevalence, with 20-40% men aged 60-69 years affected 1 . The 61 genetic architecture of ED remains poorly understood, owing in part to a paucity of well-powered 62 genetic association studies. 63
64
We conducted a genome-wide association study (GWAS) using data from the population-based UK 65 Biobank (UKBB) and the Estonian Genome Center of the University of Tartu (EGCUT) cohorts and 66 hospital-recruited Partners HealthCare Biobank (PHB) cohort ( Supplementary Methods) . 67
68
The prevalence of ED (defined as self-reported, or physician-reported ED using ICD10 codes N48.4 69 and F52.2, or use of oral ED medication (sildenafil/Viagra, tadalafil/Cialis or vardenafil/Levitra), or a 70 history of surgical intervention for ED (using OPCS-4 codes: L97.1 and N32.6)) in the cohorts was 71 1.53% (3,050/199,352) in UKBB, 7.04% (1,182/16,787) in EGCUT and 25.35% (1,943/7,666) in PHB 72 (Supplementary Table 1 ). 73 74 GWAS in UKBB revealed a single genome-wide significant (p < 5×10 -8 ) locus at 6q16. 3 
(Figures 1A 75
and 1B; lead variant, rs57989773, EAFUKBB (C-allele) = 0.24; OR 1.23; p = 3.0×10 -11 ). Meta-analysis 76 with estimates from PHB (OR 1.20; p = 9.84×10 -5 ) and EGCUT (OR 1.08; p = 0.16) yielded a pooled 77 meta-analysis OR 1.20; p = 5.72×10 -14 ( Figure 1C ). Meta-analysis of all variants yielded no further 78 genome-wide loci. Meta-analysis of our results with previously suggested ED-associated variants did 79 not result in any further significant loci (Supplementary Methods; Supplementary Table 2) . 80
81
The association of rs57989773 was consistent across clinically-and therapy-defined ED and across 82 different ED drug classes ( Figure 1C and Supplementary Figure S1 ). No further genome-wide 83 significant loci were identified for ED when limited to clinically-or therapy-defined cases 84 (Supplementary Notes). 85
86
A PheWAS of 105 predefined traits ( Supplementary Table 3 ) using the lead ED SNP rs57989773 found 87 associations with 12 phenotypes at p-value < 5×10 -4 (surpassing the Bonferroni-corrected threshold of 88 0.05/105), including adiposity (9 traits), adult height and sleep-related traits. Sex-stratified analyses 89 revealed sexual dimorphism for waist-hip ratio (WHR), systolic and diastolic blood pressure ( Figure  90 1D and Supplementary Table 4 ). 91 92 rs57989773, the lead variant at the 6q16.3 locus, lies in the intergenic region between MCHR2 and 93 SIM1, with MCHR2 being the closest gene (distances to transcription start sites of 187kb for MCHR2 region (rs9321659) was not in LD with our lead variant (r 2 =0.003) and was not associated with ED (p 97 = 0.32) in our meta-analysis, suggesting that the ED locus represents an independent signal. 98
99
To identify the tissue and cell types in which the causal variant(s) for ED may function, we examined 100 chromatin states across 127 cell types 3, 4 for the lead variant rs57989773 and its proxies (r 2 >0.8, 101 determined using HaploReg v4.1 (Supplementary Methods)). Enhancer marks in several tissues, 102
including embryonic stem cells, mesenchymal stem cells and endothelial cells, indicated that the ED-103 associated interval lies within a regulatory locus (Figure 2A , Supplementary Table 5 ). 104
105
To predict putative targets and causal transcripts, we assessed domains of long-range three-dimensional 106 chromatin interactions surrounding the ED-associated interval ( Figure 2B ). Chromosome conformation 107 capture (Hi-C) in human embryonic stem cells 5 showed that MCHR2 and SIM1 were in the same 108 topologically associated domain (TAD) as the ED-associated variants, with high contact probabilities 109 (referring to the relative number of times that reads in two 40-kb bins were sequenced together) between 110 the ED-associated interval and SIM1 ( Figure 2B and Figure S2 ). 111
112
This was further confirmed in endothelial precursor cells 6 , where Capture Hi-C revealed strong 113 connections between the MCHR2-SIM1 intergenic region and the SIM1 promoter ( Figure 2C ), pointing 114 towards SIM1 as a likely causal gene at this locus. 115
116
We next used the VISTA enhancer browser 7 to examine in vivo expression data for non-coding elements 117 within the MCHR2-SIM1 locus. A regulatory human element (hs576), located 30-kb downstream of the 118 ED-associated interval, seems to drive in vivo enhancer activity specifically in the midbrain 119 (mesencephalon) and cranial nerve in mouse embryos ( Figure 2D ). This long-range enhancer close to 120 ED-associated variants recapitulated aspects of SIM1 expression ( Figure 2D ), further suggesting that 121 the ED-associated interval belongs to the regulatory landscape of SIM1. Taken together these data 122
suggest that the MCHR2-SIM1 intergenic region harbors a neuronal enhancer and that SIM1 is 123 functionally connected to the ED-associated region. 124 125 Single-minded homolog 1 (SIM1) encodes a transcription factor that is highly expressed in 126 hypothalamic neurons 8 . Rare variants in SIM1 have been linked to a phenotype of severe obesity and 127 autonomic dysfunction 9,10 , including lower blood pressure. A summary of the variant-phenotype 128 associations at the 6q16 locus in human and rodent models is shown in Supplementary Table 6 . Post-129 hoc analysis of association of rs57989773 with autonomic traits showed nominal association with 130 suggesting that SIM1 is the causal gene at the ED-risk locus. Sim1-expressing neurons also play an 134 important role in the central regulation of male sexual behavior as mice that lack the melanocortin 135 receptor 4 (MC4R) specifically in Sim1-expressing neurons show impaired sexual performance on 136 mounting, intromission, and ejaculation 11 . Thus, hypothalamic dysregulation of SIM1 could present a 137 potential mechanism for the effect of the MCHR2-SIM1 locus on ED. 138 139 An additional functional mechanism may be explained by proximity of the lead variant (rs57989773) 140
to an arginase 2 processed pseudogene (LOC100129854), a long non-coding RNA (Figure 2A) . 141
RPISeq 12 predicts that the pseudogene transcript would interact with the ARG2 protein, with 142 probabilities of 0.70-0.77. Arginine 2 is involved in nitric oxide production and has a previously 143 established role in erectile dysfunction 13, 14 . GTEX expression data 15 demonstrated highest mean 144 expression in adipose tissue, with detectable levels in testis, fibroblasts and brain. Expression was 145 relatively low in all tissues however, and there was no evidence that any SNPs associated with the top 146 ED signal were eQTLs for the ARG2 pseudogene or ARG2 itself. Supplementary Tables 7-9 ). GARFIELD analyses also 155 did not yield any statistically significant enrichments. 156 157 LD score regression 18,19 identified ED to be correlated and share genetic architecture with type 2 158 diabetes (rg = 0.40, nominal p-value = 0.0008; FDR-adjusted p-value = 0.0768; Supplementary Table  159 10). Mendelian randomization 20 (Supplementary Tables 11-17) identified genetic risk to T2D to be 160 causally implicated in ED: OR 1.11 (95% CI 1.05-1.17, p = 3.5×10 -4 , per 1-log higher genetic risk of 161 T2D; with insulin resistance likely representing a mediating pathway. A potential causal effect of SBP 162 was also identified, with higher SBP being linked to higher risk of ED. In keeping with this, genetic 163 risk of CHD showed weak effects on risk of ED, suggesting that pathways leading to CHD may be 164 implicated in ED. 165
166
In contrast, no causal effects of BMI (using a polygenic score or a single SNP in FTO) or education on 167
We also looked at variation at the 4q26 locus, containing PDE5A which encodes phosphodiesterase 5 171 (PDE5) -the primary drug target for PDE5-inhibitors such as sildenafil. Of all 4,670 variants within a 172 1Mb window of PDE5A (chromosome 4:119,915,550 -121,050,146 as per GRCh37/hg19), the variant 173 with the strongest association was rs115571325, 26Kb upstream from PDE5A (ORMeta 1.25, nominal p-174 value = 8.46 x 10 -4 ; Bonferroni-corrected threshold (0.05/4,670) = 1.07 x 10 -5 ; Figure S4 ). 175
176
In conclusion, our GWAS of 6,175 ED cases, the largest to date, identifies a new locus associated with 177 ED, and provides evidence implicating an effect of common non-coding variants on SIM1. We also 178
show genetic risk to T2D as causally implicated in the aetiology of ED, with suggestive evidence for 179 blood pressure and coronary heart disease. Further large-scale GWAS of ED are needed in order to 180 provide additional clarity on its genetic architecture, aetiology and shed light on potential new therapies. C: The association of rs57989773 with ED shows a consistent direction of effect across the three cohorts and across clinically-and therapy-defined ED in UKBB.
D: PheWAS reveals sex-specific associations of rs57989773 with waist-hip ratio and blood pressure. A PheWAS of 105
predefined traits using the lead ED SNP rs57989773 found associations with 12 phenotypes at p-value < 4.8 × 10 -4 (surpassing the Bonferroni-corrected threshold of 0.05/105; Supplementary Table 3 ). Due to the nature of the ED phenotype and previously reported sex-specific effects in the MCHR2-SIM1 locus, sex-specific analyses were performed in significant traits. Diastolic blood pressure (dbp) and systolic blood pressure (sbp) are included here (despite not meeting the Bonferroni-corrected threshold in the original analysis), due to previous reports of effects on blood-pressure in patients with rare, coding variants in SIM1 and because the female-specific effects on blood pressure did meet the original threshold. Sexual heterogeneity was found to be significant (surpassing a Bonferroni-corrected threshold of 0.05/7 for the number of traits where sex-specific analyses were conducted) for diastolic blood pressure (p-value heterogeneity = 6.52 × 10 -3 ), systolic blood pressure (p-value heterogeneity = 3.73 × 10 -3 ), waist to hip ratio (p-value heterogeneity = 2.39 × 10 -6 ) and waist to hip ratio adjusted for BMI (p-value heterogeneity = 1.77 × 10 -5 ). Continuous traits were standardised prior to analysis to facilitate comparison. 
